# Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy

> **NCT06299202** · NA · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Diagnostic test

## Key facts

- **NCT ID:** NCT06299202
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299202, "Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06299202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*